与皮下注射 C1INH 预防遗传性血管性水肿相关的患者疗效:回顾性分析

William Lumry, Timothy Craig, John Anderson, Marc Riedl, Henry Li, Raffi Tachdjian, Michael Manning, Paolo Bajcic, Frank Rodino, Sam Wang, Thomas R. Sexton, Jonathan A. Bernstein
{"title":"与皮下注射 C1INH 预防遗传性血管性水肿相关的患者疗效:回顾性分析","authors":"William Lumry, Timothy Craig, John Anderson, Marc Riedl, Henry Li, Raffi Tachdjian, Michael Manning, Paolo Bajcic, Frank Rodino, Sam Wang, Thomas R. Sexton, Jonathan A. Bernstein","doi":"10.1186/s13223-023-00861-9","DOIUrl":null,"url":null,"abstract":"Real-world data on subcutaneous C1INH (C1INH[SC]) usage and patient-level impacts on hereditary angioedema (HAE)-related outcomes and quality of life (QoL) are both lacking and challenging to generate using conventional study methodologies. Using a hybrid study design involving patient interviews supplemented by retrospective medical chart data review, we conducted a real-world assessment of the impact of C1INH(SC) prophylaxis on HAE attack patterns, QoL, and on-demand medication use. The study was conducted at seven US sites and included 36 adults with HAE who had been treated with C1INH(SC) long-term prophylaxis following ≥ 12 months of on-demand management only. Patients underwent 30-min interviews, facilitated and analyzed by a trained qualitative research specialist. Medical records were reviewed for 12 months before (pre-index) and after (post-index) initiation of C1INH(SC). Using interview data with descriptive terms converted to numerical values, we compared pre- versus post-index attack frequency, severity, and rescue medication usage. Mean (SD) annualized attack frequency per patient decreased 82.0%, from 38.8 (38.8) attacks/year pre-index to 7.0 (15.3) attacks/year (P < 0.001); the median number of attacks decreased by 97.0% (30 pre-index to 1 post-index). For 20 patients, the annualized attack rate after starting C1INH(SC) prophylaxis was ≤ 1 attack/year; 12 of these patients reported 0 attacks. Mean (SD) attack severity (scale: 0 = none/mild to 4 = very severe) decreased from 2.3 (0.7) pre-index to 0.9 (0.9) post-index (P < 0.001). Mean/median rescue medication use decreased by 77.2%/96.3%. Improved QoL was narratively described for many domains. These real-world findings indicate that long-term prophylaxis with C1INH(SC) markedly improves important factors that contribute to the goal of achieving total disease control and normalization of patients’ lives, including fewer and less severe attacks, less rescue medication usage, and improved QoL.","PeriodicalId":501611,"journal":{"name":"Allergy, Asthma & Clinical Immunology","volume":"5 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Patient outcomes associated with subcutaneous C1INH prophylaxis for hereditary angioedema: a retrospective analysis\",\"authors\":\"William Lumry, Timothy Craig, John Anderson, Marc Riedl, Henry Li, Raffi Tachdjian, Michael Manning, Paolo Bajcic, Frank Rodino, Sam Wang, Thomas R. Sexton, Jonathan A. Bernstein\",\"doi\":\"10.1186/s13223-023-00861-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Real-world data on subcutaneous C1INH (C1INH[SC]) usage and patient-level impacts on hereditary angioedema (HAE)-related outcomes and quality of life (QoL) are both lacking and challenging to generate using conventional study methodologies. Using a hybrid study design involving patient interviews supplemented by retrospective medical chart data review, we conducted a real-world assessment of the impact of C1INH(SC) prophylaxis on HAE attack patterns, QoL, and on-demand medication use. The study was conducted at seven US sites and included 36 adults with HAE who had been treated with C1INH(SC) long-term prophylaxis following ≥ 12 months of on-demand management only. Patients underwent 30-min interviews, facilitated and analyzed by a trained qualitative research specialist. Medical records were reviewed for 12 months before (pre-index) and after (post-index) initiation of C1INH(SC). Using interview data with descriptive terms converted to numerical values, we compared pre- versus post-index attack frequency, severity, and rescue medication usage. Mean (SD) annualized attack frequency per patient decreased 82.0%, from 38.8 (38.8) attacks/year pre-index to 7.0 (15.3) attacks/year (P < 0.001); the median number of attacks decreased by 97.0% (30 pre-index to 1 post-index). For 20 patients, the annualized attack rate after starting C1INH(SC) prophylaxis was ≤ 1 attack/year; 12 of these patients reported 0 attacks. Mean (SD) attack severity (scale: 0 = none/mild to 4 = very severe) decreased from 2.3 (0.7) pre-index to 0.9 (0.9) post-index (P < 0.001). Mean/median rescue medication use decreased by 77.2%/96.3%. Improved QoL was narratively described for many domains. These real-world findings indicate that long-term prophylaxis with C1INH(SC) markedly improves important factors that contribute to the goal of achieving total disease control and normalization of patients’ lives, including fewer and less severe attacks, less rescue medication usage, and improved QoL.\",\"PeriodicalId\":501611,\"journal\":{\"name\":\"Allergy, Asthma & Clinical Immunology\",\"volume\":\"5 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-12-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Allergy, Asthma & Clinical Immunology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1186/s13223-023-00861-9\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Allergy, Asthma & Clinical Immunology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s13223-023-00861-9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

关于皮下注射 C1INH(C1INH[SC])的使用情况以及患者层面对遗传性血管性水肿(HAE)相关结果和生活质量(QoL)的影响的真实世界数据既缺乏,使用传统研究方法也很难获得。我们采用混合研究设计,包括患者访谈和回顾性病历数据审查,对 C1INH(SC) 预防对 HAE 发作模式、生活质量和按需用药的影响进行了实际评估。这项研究在美国 7 个地点进行,包括 36 名成年 HAE 患者,他们在接受≥ 12 个月的按需用药治疗后接受了 C1INH(SC) 长期预防治疗。患者接受了 30 分钟的访谈,访谈由经过培训的定性研究专家协助和分析。对开始使用 C1INH(SC) 前(指数前)和后(指数后)12 个月的病历进行了审查。利用将描述性术语转换为数值的访谈数据,我们比较了指数前和指数后的发作频率、严重程度和抢救药物使用情况。每位患者的平均(标清)年发作频率下降了 82.0%,从指数前的 38.8 (38.8) 次/年降至 7.0 (15.3) 次/年(P < 0.001);发作次数中位数下降了 97.0%(指数前为 30 次/年,指数后为 1 次/年)。20名患者在开始使用C1INH(SC)预防治疗后,年发作率低于1次/年;其中12名患者报告为0次发作。发作严重程度的平均值(标度)(从 0 = 无/轻微到 4 = 非常严重)从指数前的 2.3 (0.7) 降至指数后的 0.9 (0.9)(P < 0.001)。抢救用药的平均/中位数分别减少了 77.2%/96.3% 。许多领域的 QoL 都得到了改善。这些真实世界的研究结果表明,长期使用C1INH(SC)预防可明显改善有助于实现疾病完全控制和患者生活正常化目标的重要因素,包括减少和减轻发作、减少抢救药物的使用以及改善 QoL。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Patient outcomes associated with subcutaneous C1INH prophylaxis for hereditary angioedema: a retrospective analysis
Real-world data on subcutaneous C1INH (C1INH[SC]) usage and patient-level impacts on hereditary angioedema (HAE)-related outcomes and quality of life (QoL) are both lacking and challenging to generate using conventional study methodologies. Using a hybrid study design involving patient interviews supplemented by retrospective medical chart data review, we conducted a real-world assessment of the impact of C1INH(SC) prophylaxis on HAE attack patterns, QoL, and on-demand medication use. The study was conducted at seven US sites and included 36 adults with HAE who had been treated with C1INH(SC) long-term prophylaxis following ≥ 12 months of on-demand management only. Patients underwent 30-min interviews, facilitated and analyzed by a trained qualitative research specialist. Medical records were reviewed for 12 months before (pre-index) and after (post-index) initiation of C1INH(SC). Using interview data with descriptive terms converted to numerical values, we compared pre- versus post-index attack frequency, severity, and rescue medication usage. Mean (SD) annualized attack frequency per patient decreased 82.0%, from 38.8 (38.8) attacks/year pre-index to 7.0 (15.3) attacks/year (P < 0.001); the median number of attacks decreased by 97.0% (30 pre-index to 1 post-index). For 20 patients, the annualized attack rate after starting C1INH(SC) prophylaxis was ≤ 1 attack/year; 12 of these patients reported 0 attacks. Mean (SD) attack severity (scale: 0 = none/mild to 4 = very severe) decreased from 2.3 (0.7) pre-index to 0.9 (0.9) post-index (P < 0.001). Mean/median rescue medication use decreased by 77.2%/96.3%. Improved QoL was narratively described for many domains. These real-world findings indicate that long-term prophylaxis with C1INH(SC) markedly improves important factors that contribute to the goal of achieving total disease control and normalization of patients’ lives, including fewer and less severe attacks, less rescue medication usage, and improved QoL.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信